百济神州大中华区首席商务官殷敏被带走调查，或涉此前阿斯利康“骗保案”

Core Viewpoint - The investigation of Yin Min, Chief Commercial Officer of BeiGene in Greater China, has led to a significant drop in the company's stock price, raising concerns about potential implications for the company and its operations [1]. Group 1: Company Developments - Yin Min was taken away for investigation related to the previous AstraZeneca "insurance fraud" incident, which has seen multiple individuals involved being questioned [1]. - BeiGene's stock price fell over 10% following the news but later rebounded, closing down more than 3% at 173.00 yuan per share [1]. - Since joining BeiGene in January 2022, Yin Min has overseen significant achievements, including the expansion of indications for Zebrutinib in the U.S. and the approval of Tislelizumab in major markets [1]. Group 2: Financial Performance - BeiGene reported revenues of 9.566 billion yuan in 2022 and 17.423 billion yuan in 2023, indicating substantial growth [1]. - The company is expected to narrow its losses starting in 2024, with a non-GAAP profit achieved in the second quarter, aiming for breakeven [1]. Group 3: Background of Yin Min - Yin Min has a background in finance and computer science, with previous experience at multinational pharmaceutical companies, including a 15-year tenure at AstraZeneca [1]. - During her time at AstraZeneca, she held various senior positions, including Vice President of the Oncology Business Unit in China [1][2].